2014 News Releases

Webcast ImageWebcast - Replay
AtriCure, Inc. at the Piper Jaffray 26th Annual Healthcare Conference
12/03/14 at 11:00 a.m. ET
AtriCure, Inc. at the Piper Jaffray 26th Annual Healthcare Conference
Wednesday, December 3, 2014 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
11/03/14AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients
AtriCure will investigate a minimally invasive approach to treat patients with persistent or long-standing persistent atrial fibrillation who have failed antiarrhythmic drug therapy. WEST CHESTER, Ohio--(BUSINESS WIRE) November 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug A... 
Printer Friendly Version
10/31/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Stifel Healthcare Conference 2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014. Management is scheduled to present at 3:35 p.m. Eastern Time. A live audio webcast and replay of the presentation will be a... 
Printer Friendly Version
10/30/14AtriCure Reports Third Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.7 million – up 32.4% U.S. sales of $20.1 million – up 26.7% International sales of $6.6 million – up 53.4%; 53.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 30, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced financial results for the third ... 
Printer Friendly Version
10/09/14AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 3... 
Printer Friendly Version
10/03/14AtriCure to Announce Third Quarter 2014 Financial Results
WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 30, 2014 to discuss its third quarter 2014 financial results. A live webcast of the conference call will be available online fro... 
Printer Friendly Version
09/18/14AtriCure Announces the Release of the AtriClip® FLEX
Increased shaft flexibility allows a surgeon more maneuverability within a patient’s unique anatomy when excluding the left atrial appendage WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and Left Atrial Appendage Management (LAAM), today announced the introduction of the AtriClip® FLEX, a new device with a more flexible... 
Printer Friendly Version
07/29/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following th... 
Printer Friendly Version
07/24/14AtriCure Reports Second Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.5 million – up 29.8% U.S. sales of $19.9 million – up 28.8% International sales of $6.6 million – up 32.9%; 29.1% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the second quarter of 2014. “We are pleased with our performan... 
Printer Friendly Version
07/16/14AtriClip® System Surpasses 34,000 Units Sold
AtriClip is the most widely used device indicated for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 16, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), today announced that it has sold more than 34,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, quickly becoming the top selling device used for eliminating the left... 
Printer Friendly Version
07/03/14AtriCure to Announce Second Quarter 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the second quarter of 2014 on Thursday, July 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, July 24, 2014 to discuss its second quarter 2014 financial results. A live webcast of the conference call will be available online from... 
Printer Friendly Version
05/28/14AtriCure to Present at the 9th Annual JMP Securities Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--May 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the 9th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Tuesday, June 24, 2014. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 90 days follo... 
Printer Friendly Version
05/21/14AtriCure Announces First Patient Enrolled in Stroke Feasibility Study
First U.S. clinical study to evaluate the safety of a novel epicardial-based left atrial appendage closure device for stroke prevention in atrial fibrillation patients. WEST CHESTER, Ohio--(BUSINESS WIRE)--May 21, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leader in surgical solutions to treat atrial fibrillation (Afib), today announced the first patient enrolled in a feasibility study using the AtriClip® Left Atrial Appendage Exclusion Sy... 
Printer Friendly Version
04/24/14AtriCure Reports First Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $24.8 million – up 27.9% U.S. sales of $18.1 million – up 23.9% International sales of $6.7 million – up 39.9%; 36.4% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the first quarter of 2014. “We are off to a strong start in 20... 
Printer Friendly Version
04/04/14AtriCure to Announce First Quarter 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the first quarter of 2014 on Thursday, April 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 24, 2014 to discuss its first quarter 2014 financial results. A live webcast of the conference call will be available online from... 
Printer Friendly Version
02/28/14AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 day... 
Printer Friendly Version
02/27/14AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
2013 revenue of $81.9 million – up 16.6% 2013 U.S. sales of $62.3 million – up 18.4% Fourth quarter revenue of $21.9 million – up 19.2% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 27, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced fourth quarter and full year 2013 financial results. “We are pleased with our team’s performanc... 
Printer Friendly Version
02/13/14AtriCure Prices Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 13, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, Atr... 
Printer Friendly Version
02/12/14AtriCure Announces Commencement of Public Offering of Common Stock
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 12, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds... 
Printer Friendly Version
02/04/14AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 27, 2014 to discuss its fourth quarter and full year 2013 financial results. A live webcast of the conference call wil... 
Printer Friendly Version
01/20/14AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 20, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Leerink Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12, 2014. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 3... 
Printer Friendly Version
01/09/14AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2013 and Issues 2014 Guidance
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance. Preliminary revenue for the fourth quarter of 2013 is expected to be approximately $21.9 million, reflecting growth of approximately 19% over the fourth quarter of 2012. Based on this prelimin... 
Printer Friendly Version
01/02/14AtriCure Completes Acquisition of Estech
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 2, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech (“Estech”). Estech develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech’s pro... 
Printer Friendly Version